Novel therapeutic approach for kidney fibrosis
|
|
|
- Lesley Taylor
- 5 years ago
- Views:
Transcription
1 University of Sydney Novel therapeutic approach for kidney fibrosis DAVID HARRIS 30/09/17 Westmead Hospital
2 Cadnapaphornchai CJASN 2014;9:889
3 Liraglutide: Renal Outcomes Mann JFE et al. N Engl J Med 2017;377: GLP-1ra
4 Canagliflozin: Renal Outcomes Neal B et al. N Engl J Med 2017;377: Integrated CANVAS Program SGLT2 inhibitor
5 Torres et al. NEJM 2012 Tolvaptan in early-stage ADPKD
6 Non diabetic CKD not attractive for pharma Population heterogeneity Absence of reliable biomarkers for subgroup selection Absence of reliable surrogates (efficacy biomarkers) Large subject numbers Long follow-up
7 Some novel therapies in human CKD Pirfenidone: study withdrawn Nox1/4 inhibitor negative trial Anti-CTGF antibodies FG3019: studies terminated SSAO/ VAP1 inhibitors: phase 1 clinical trial concluded, not reported Curcumin phase 3 trial completed, not reported Tranilast and analogues FT011: in phase 1b clinical trial Alpha-lipolic acid: recruiting Tie2 Rec activator - angiopoietin receptor, tyrosine kinase inhibitor: in development JAK-STAT inhibitors: in development LOX inhibitors: in development Anti TGF-b Ab (LY ) negative trial
8 FGS trial terminated N=36 DB, randomised Vincenti F et FGS Study Group KIR 2017:2:
9 TGF-β1 mab for DN trial terminated N=416 DB, randomised phase 2 Voelker J et al. JASN 2017;28:
10 BMP7 and TGFβ1 are better predictors of major renal endpoints than egfr+uacr baseline serum a nested case-control study of ADVANCE participants with renal endpoint (n=1000) type 2 diabetes Wong MG et al. Kidney Int 2013;83:278-84
11 TRANSLATION OF SMALL MOLECULAR ANTI-FIBROTICS N=63, mainly for respiratory (IPF), liver (NASH, NAFLD), and skin (scleroderma, keloid) diseases N=11 for renal disease Pirfenidone multiple diabetic nephropathy (DN, phase 2, completed) F-351 p38 (a,g) inh (liver &) kidney fibrosis (phase 1b/11) Atrasentan sel ETAr inh DN (phase 111, SONAR) GKT NOX1 & NOX4 inh DN (phase 11) Bardoxolone NRF2-KEALi act CKD & DN (phase 111, terminated safety) Baricitinib JAK1 & JAK2 inh DN (phase 11) Emricasan pan-caspase inh severe renal impairment (phase 1) prostacyclin analogue primary glom disease (phase 11b/111) Beraprost CTP-499 pan-pde inh DN (phase 11, completed) Pyridoxamine metabolite of vit B6 DN (phase 11, completed) Bindarit CCL3, -7, -8 inh DN (phase 11, completed) Nanthakumar CB et al. Nat Rev Drug Discovery 2015;14:
12 TGF-b: the master regulator of fibrosis Meng X-M et al. NRN 2016;12:325-38
13 TGF-β causes tissue fibrosis through three major Signaling Pathways + Anti-inflammation Wound healing Hypothesis: β-catenin/foxo is the key target to dissociate profibrotic from anti-inflammatory and wound-healing effects of TGF-β
14 Inhibition of β-catenin/tcf should increase β-catenin/foxo binding Both TCF & Foxo bind to the Armadillo repeats 1-7 of β-catenin Foxo or TCF ICG-001, a peptidomimetic small molecule, selectively inhibits β-catenin/tcf in a CBP-dependent manner
15 TGF-β and regulatory T cells are key regulators of inflammation
16 Anti-fibrotic effect of β-catenin/foxo
17 E-cadherin Vimentin WT KO FoxO1 β-catenin/foxo1 protects against TGF-β-induced profibrotic changes in vitro %Vimentin area %E-cadherin area WT Foxo1KO KO FoxO1 WT Control rhtgf-β1 rhtgf-β1+icg-001 ICG- 001 ICG-001 Control rhtgf-β1 rhtgf-β1+icg-001 ICG-001 WT Foxo1KO Control rhtgf-β1 rhtgf-β1+icg-001 ICG-001 Control rhtgf-β1 rhtgf-β1+icg-001 ICG-001
18 rhtgf-β1+icg-001 increases β-catenin/foxo in UUO kidney proximity ligation assay UUO (U) UUO + rhtgfβ1 + ICG (U+T +I) * UUO + rhtgfβ1 (U+T) U U+T U+T+I
19 Interstitial Fibrosis % Inhibition of β-catenin/tcf interaction by ICG-001 decreases kidney fibrosis in UUO *
20 Inhibition of β-catenin/tcf by ICG-001 increases β-catenin/foxo1 in kidney of UUO mice proximity ligation assay
21 β-catenin/foxo1 protects against kidney fibrosis in UUO
22 β-catenin/tcf β-catenin/foxo β-catenin/foxo1/tcf in human diabetic nephropathy & kidney transplant Diabetic Nephropathy (r= ) Transplant kidney (r= ) P<0.01 Diabetic Nephropathy (r=0.9223) Transplant kidney (r=0.7643) P<0.01 Proximity ligation assay Fibrosis score
23 Renal β-catenin/foxo1/tcf in human CKD Transplant Diabetic nephropathy r=0.763 r= r=0.948 r= Hypertension IgA nephropathy r=0.925 r=0.914 r= r= Proximity ligation assay
24 Treg-dependent anti-inflammatory effect of β-catenin/foxo
25 Infiltrated cells/10 HP Inhibition of β-catenin/tcf interaction by ICG-001 reduces inflammation via itreg in UUO kidney Sham control UUO Pc61+UUO+ TGFβ1+ICG-001 UUO+TGFβ1 UUO+ICG- 001 UUO+TGF- β1+icg- 001 Pc61+UUO+ TGF-β 1+ICG-001 Sham control UUO UUO+ TGF-β1 UUO+ICG-001 UUO+ TGFβ1+ICG * # # *P < 0.05 vs control # p < 0.05 vs untreated UUO p < 0.05 vs TGF-β1 treated UUO
26 Percent F4/80 Area Inhibition of β-catenin/tcf interaction by ICG-001 reduces macrophage infiltration via itreg in UUO kidney Sham control UUO Pc61+UUO+ TGFβ1+ICG-001 UUO+TGFβ1 UUO+ICG- 001 UUO+TGF- β1+icg- 001 Pc61+UUO+ TGF-β 1+ICG-001 Sham control UUO UUO+ TGF-β1 UUO+ICG-001 UUO+ TGFβ1+ICG * # # *P < 0.05 vs control # p < 0.05 vs untreated UUO p < 0.05 vs TGF-β1-treated UUO
27 Interstitial fibrosis (%) Inhibition of β-catenin/tcf interaction by ICG-001 decreases kidney fibrosis, in part by itregs Sham control UUO UUO+ TGF-β1 UUO+ICG-001 UUO+ TGFβ1+ICG-001 Pc61+UUO+ TGFβ1+ICG Sham control * UUO # # UUO+TGFβ1 UUO+ICG- 001 UUO+TGF- β1+icg- 001 Pc61+UUO+ TGF-β 1+ICG-001 *P < 0.05 vs control # p < 0.05 vs untreated UUO p < 0.05 vs TGF-β1-treated UUO
28 rhtgf-β1 + ICG-001 reduces kidney fibrosis after unilateral ischaemia reperfusion, via Tregs
29 Liver fibrosis score Inhibition of β-catenin/tcf interaction by ICG-001 prevents TGF-β1- induced distant organ fibrosis (liver) # Sham control UUO UUO+TGF-β1 UUO+ICG-001 UUO+TGF-β 1+ICG-001 # p < 0.05 vs untreated UUO p < 0.05 vs TGF-β1-treated UUO
30 Lung fibrotic area (%) Inhibition of β-catenin/tcf interaction by ICG-001 prevents TGF-β1- induced distant organ fibrosis (lung) Sham control # UUO UUO+TGF-β1 UUO+ICG-001 UUO+TGF-β 1+ICG-001 # p < 0.05 vs untreated UUO p < 0.05 vs TGF-β1-treated UUO
31 non-fibrotic wound-healing effect of β-catenin/foxo in kidney injury
32 ICG-001 promotes non-fibrotic wound healing in rhtgf-β1 treated C1.1 cells Scratch Assay IF staining of E-cadherin / α-sma * # E-cadherin α-sma * # * P < 0.01 vs. control; # P < 0.01 vs. TGF-β
33 KO TCF1 KO FoxO1 WT Wound healing assay 48 h Control TGF-β TGF-β + ICG-001 ICG-001
34 Therapeutic targeting β-catenin/foxo by inhibition of β- catenin/tcf. reduces fibrosis (kidney, lung, liver) infiltration of lymphocytes & macrophages, (Treg-dependent) increases non-fibrotic wound healing
35 TARGETING INFLAMMATION DNA VACCINATION chemokines/receptors: CCL2, CCL5, CX3CR1 costimulatory molecules: CD40 INHIBITING EFFECTOR CELLS REGULATORY CELLS (mesenchymal stem cells) protective macrophages: M2a, M2c, Mreg tolerogenic dendritic cells regulatory lymphocytes regulatory innate lymphoid cells
36 anti-inflammatory macrophages may be profibrotic (in vitro) Which macrophages are pro-fibrotic? Proinflammatory (M1) Suppressor (M2c) Wound-healing (M2a) Fibrinolytic NO NO YES* NO *but our studies show net effect in vivo is anti-fibrotic
37 M2a or M2c in Adriamycin nephropathy M2c > M2a: proteinuria, tubular cell atrophy, interstitial CD4 infiltration
38 Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury O Connell PJ et al. Lancet 2016;388:983-93
39 IDENTIFYING PATHOGENIC GENE PATHWAYS IN RENAL TRANSPLANT FIBROSIS identify kidney transplants at risk of chronic injury Biopsy transcriptome expression profiling evaluate profibrotic potential of genes predictive of progressive graft fibrosis deletional mutations in cell lines deletional mutations in zebrafish determine the importance of HIF-1a and Wnt/β-catenin in progressive graft fibrosis conditional knockout O Connell PJ, Grey S, Harris D, Zheng G, Yi S.
40 Renal MRI for function & severity of fibrosis diffusion-weighted MRI blood oxygen level dependent MRI MR elastography susceptibility imaging Morrell GR et al. JASN 2017;28: show promise but currently limited accuracy & practicality further development
41 Kirpalani A et al. CJASN 2017 MR elastography: heterogeneous kidney stiffness
42 MR elastography stiffness scores may predict future changes in kidney allograft function Kirpalani A et al. CJASN 2017
43 TARGET FIBROSIS INHIBIT β-catenin/tcf STIMULATE β-catenin/foxo evaluate profibrotic potential of genes predictive of progressive fibrosis TARGET INFLAMMATION DNA VACCINATION INHIBIT EFFECTOR CELLS REGULATORY CELLS MSCs, Mf, DCs, Tregs, ILCs
44
renoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
ROS as targets for therapeutic intervention of diabetic nephropathy
36 th Autumn Congress of Korean Diabetes Association September 16-17, 2010, BEXCO, Busan, Korea ROS as targets for therapeutic intervention of diabetic nephropathy Hunjoo Ha Department of Bioinspired Science
T Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
New Treatments for ADPKD how close are we?
New Treatments for ADPKD how close are we? Leicester General Hospital 28 Jan 2012 Professor Albert Ong a.ong@sheffield.ac.uk The cystic degeneration of the kidneys, once it reaches the point where it can
Hasan Fattah 4/30/2013
Hasan Fattah 4/30/2013 49 yo hispanic male, ho HIV(CD4 229), currently on HAART, course c/b AIDS, Presents with two days ho fever, SOB, blood tinged sputum, and visible hematuria. ROS: no skin rash, joint
FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant
Prof. Sandrine Florquin Department of Pathology Academic Medical Center University of Amsterdam Amsterdam, The Netherlands. Slide 1.
Interleukin 17 in renal biopsies as risk factor for progression Sandrine Florquin, Amsterdam, The Netherlands Chairs: Mohamed R. Daha, Leiden, The Netherlands Pierre Ronco, Paris, France Prof. Sandrine
Darwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
DMX-200 for Diabetic Kidney Disease
DMX-200 for Diabetic Kidney Disease A/Prof David Packham MBBS(Hons), FRCP, FRACP, ARCP, MD Chief Medical Officer, Dimerix Nephrologist Bioshares Summit Queenstown, New Zealand 27 July 2018 Disclaimer Some
Analysis of regulatory T cell subsets in the peripheral blood of immunoglobulin A nephropathy (IgAN) patients
Analysis of regulatory T cell subsets in the peripheral blood of immunoglobulin A nephropathy (IgAN) patients S. Yang, B. Chen, J. Shi, F. Chen, J. Zhang and Z. Sun Department of Nephrology, Huaihe Hospital
Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9
Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S1A9 Joanna Nikitorowicz-Buniak UCL Division of Medicine Systemic sclerosis
T cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
Time Program Speakers
Program APSN/HKSN CME Course Saturday, 30 Sep 2017 Venue: Pao Yue Kong Auditorium, Hong Kong Academy of Medicine Time Program Speakers 13:45 14:00 Registration 14:00 14:10 Opening Address (1) Chairman,
KD025 in IPF: Topline Results
KD025 in IPF: Topline Results Webcast Presentation February 13, 2018 Kadmon Holdings, Inc. 1 Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs
Hot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
Alessandra Franco MD PhD UCSD School of Medicine Department of Pediatrics Division of Allergy Immunology and Rheumatology
Immunodominant peptides derived from the heavy constant region of IgG1 stimulate natural regulatory T cells: identification of pan- HLA binders for clinical translation Alessandra Franco MD PhD UCSD School
Ανάπτυξη Βιοτράπεζας για την Ανίχνευση Πρώιμων Βιοδεικτών σε Ασθενείς με Χρόνια Νεφρική Νόσο
Ανάπτυξη Βιοτράπεζας για την Ανίχνευση Πρώιμων Βιοδεικτών σε Ασθενείς με Χρόνια Νεφρική Νόσο ΔΗΜΗΤΡΙΟΣ Σ. ΓΟΥΜΕΝΟΣ Νεφρολογικό και Μεταμοσχευτικό Κέντρο Πανεπιστημιακό Νοσοκομείο Πατρών Causes of chronic
Cardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
Diabetic Nephropathy
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
Niki Prakoura. Calreticulin upregulation in renal fibrosis
Calreticulin upregulation in renal fibrosis Niki Prakoura Section of Histology, Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece EuroKUP meeting, Madrid,
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
CHAPTER I INTRODUCTION. Nowadays chronic kidney disease (CKD) becomes one. of the most common diseases found in the population.
CHAPTER I INTRODUCTION I.1 Background Nowadays chronic kidney disease (CKD) becomes one of the most common diseases found in the population. Based on community survey that is held by PERNEFRI (Perhimpunan
Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
Molecular mechanisms of Fibrosis: Targets of Therapy. John P Iredale University of Edinburgh, UK
Molecular mechanisms of Fibrosis: Targets of Therapy John P Iredale University of Edinburgh, UK Take home messages: The wound healing MFBs of the liver and the hepatic macrophages are key players in progressive
1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia!
Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia! Lorenz Poellinger! Dept. of Cell and Molecular Biology! Karolinska Institutet, Stockholm, Sweden! Normoxia - O 2 availability is in balance
Immunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
Understanding Root Cause: Pathogenesis of Hepatic Fibrosis
10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis
Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
Dr Ian Roberts Oxford
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing renal failure Highlight diagnostic pitfalls. Crescentic GN: renal
Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
As outlined under External contributions (see appendix 7.1), the group of Prof. Gröne at the
3 RESULTS As outlined under External contributions (see appendix 7.1), the group of Prof. Gröne at the DKFZ in Heidelberg (Dept. of Cellular and Molecular pathology) contributed to this work by performing
1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications
Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the
Advancing Opportunities To Prevent Type 1 Diabetes
Advancing Opportunities To Prevent Type 1 Diabetes Dr. Allison Green Centre for Immunology and Infection Hull York Medical School York University Type 1 Diabetes Insulin deficiency destabilizes regulation
T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
HLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
Avances en nefroprotección en la enfermedad renal diabética Cómo prevenir sus complicaciones y cómo tratarlas
Avances en nefroprotección en la enfermedad renal diabética Cómo prevenir sus complicaciones y cómo tratarlas Jesus Egido, MD, PhD Catedrático y Director, Departamento de Medicina. Universidad Autónoma
Objectives. Abbas Chapter 11: Immunological Tolerance. Question 1. Question 2. Question 3. Definitions
Objectives Abbas Chapter 11: Immunological Tolerance Christina Ciaccio, MD Children s Mercy Hospitals and Clinics February 1, 2010 To introduce the concept of immunologic tolerance To understand what factors
Corporate Presentation
Corporate Presentation June 2018 Kadmon Holdings, Inc. 1 Disclaimers This presentation contains forward looking statements that are based on the beliefs and assumptions and on information currently available
PNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
IL-24 AND ITS ROLE IN WOUND HEALING
IL-24 AND ITS ROLE IN WOUND HEALING Nancy J. Poindexter, Ryan Williams, Garth Powis, Sunil Chada, and Elizabeth A. Grimm & Introgen Therapeutics, Inc., Houston, TX IL-24/MDA 24/MDA-77 is a Tumor Suppressor
Innate Immunity, Inflammation and Cancer
Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com
Chemokines and trefoil factor peptides in patients suffering from chronic kidney disease
Defensio dissertationis Vienna, 03.10.2017 Chemokines and trefoil factor peptides in patients suffering from chronic kidney disease Doctoral thesis at the Medical University of Vienna for obtaining the
Interventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
Reviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences
Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences Walter Royal, III, MD Professor of Neurology University of Maryland School of Medicine
Perspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)
Mechanisms of Immune Tolerance
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency
Forward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
Prof. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
KD : A Phase 2 Trial of KD025 to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF)
-207: A Phase 2 Trial of to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF) K. F. Gibson 1, F. Averill 2, T.E. Albertson 3, D. M. Baratz 4, S. Chaudhary 5,
SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
DNA vaccine, peripheral T-cell tolerance modulation 185
Subject Index Airway hyperresponsiveness (AHR) animal models 41 43 asthma inhibition 45 overview 41 mast cell modulation of T-cells 62 64 respiratory tolerance 40, 41 Tregs inhibition role 44 respiratory
Recognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
i-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
Prognosis in CKD Can we do anything about it? Rodney D Gilbert
Prognosis in CKD Can we do anything about it? Rodney D Gilbert A diagnosis of end stage renal failure implies what degree of loss of life expectancy? A. 10% B. 20% C. 30% D. 40% E. 50% F. 60% 38% 22% 16%
A Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs. European Business Development Conference Düsseldorf 24 Sept 2013
A Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs European Business Development Conference Düsseldorf 24 Sept 2013 Key facts about NOXXON Developing a new class of proprietary
Statement of Disclosure
Statement of Disclosure Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma Treatment of Acute ABMR AstraZeneca Treatment
Topic (Final-02): Immunologic Tolerance
Topic (Final-02): Immunologic Tolerance Immunologic tolerance is defined as unresponsiveness to an antigen that is induced by previous exposure to that antigen. The term arose from the experimental observation
The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases
Wermuth and Jimenez Clinical and Translational Medicine (2015) 4:2 DOI 10.1186/s40169-015-0047-4 REVIEW The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human
Biology Of Renal Tubulo-Interstitial Cells (Experimental Nephrology, 5-6)
Biology Of Renal Tubulo-Interstitial Cells (Experimental Nephrology, 5-6) If you are searched for the book Biology of Renal Tubulo- Interstitial Cells (Experimental Nephrology, 5-6) in pdf format, in that
New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
Podocyte Biology and clinical applications Dr. F. Ahmadi Professor Of Nephrology TUMS
Podocyte Biology and clinical applications Dr. F. Ahmadi Professor Of Nephrology TUMS Proteinuria is a major healthcare problem that affects several hundred million people worldwide. Proteinuria is a cardinal
Supplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS.
1 Supplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS. (a) Survival curves. WT Sham (n=5), WT CLP or WT CLP antibiotic
Chapter 13: Cytokines
Chapter 13: Cytokines Definition: secreted, low-molecular-weight proteins that regulate the nature, intensity and duration of the immune response by exerting a variety of effects on lymphocytes and/or
CMV INFECTION IN KIDNEY TRANSPLANTATION
CMV INFECTION IN KIDNEY TRANSPLANTATION PIERRE MERVILLE CHU BORDEAUX - UNIVERSITÉ BORDEAUX SEGALEN UMR-CNRS 5164 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes
Tissue microenvironments in therapeutic tolerance
REPROGRAMMING THE IMMUNE SYSTEM IN AUTOIMMUNITY AND TOLERANCE Tissue microenvironments in therapeutic tolerance Malignant tissues use multiple mechanisms to limit immune damage. The tissue microenvironment
Uncovering the mechanisms of wound healing and fibrosis
Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:
Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
Literature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Statement of Disclosure Mark
Mesenchymal Stem Cells
Mesenchymal Stem Cells Science and therapeutic applications Dirk Büscher (Former VP-R&D Cellerix) GRIFOLS SA May 10 th, 2010 EMA 1 Discovery and Definition of Mesenchymal Stem Cells MSC must be plastic-adherent
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri
Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human
Lithium toxicity. Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris
Lithium toxicity Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris Lithium Use of lithium salts as salt substitutes but recall from the marketplace in 1949 Efficient in the treatment
Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured
Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured under Th0, Th1, Th2, Th17, and Treg conditions. mrna
Immunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
Innate Immunity: (I) Molecules & (II) Cells. Part II: Cells (aka the Sentinels)
Innate Immunity: (I) Molecules & (II) Cells Stephanie Eisenbarth, M.D., Ph.D. FOCIS Advanced Course 2/19/18 Department of Laboratory Medicine Yale School of Medicine Department of Immunobiology Yale School
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune
Principles of Genetics and Molecular Biology
Cell signaling Dr. Diala Abu-Hassan, DDS, PhD School of Medicine Dr.abuhassand@gmail.com Principles of Genetics and Molecular Biology www.cs.montana.edu Modes of cell signaling Direct interaction of a
European Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1
PBI-4050, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: a comparative study with pirfenidone Presented at: Thematic Poster Session:
Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
SEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
Immunological Lung Diseases
Emphysema and Fibrosis Universitätsklinik für Pneumologie Prof. Thomas Geiser Head Div. of Pulmonary Medicine and Laboratory of Lung Research, MU50 thomas.geiser@insel.ch The healthy lung: The pathway
The transcriptome of the renal transplant biopsy: the lessons. Philip F Halloran
The transcriptome of the renal transplant biopsy: the lessons Philip F Halloran Alberta Transplant Applied Genomics Centre April 27 th 2009 Congratulations on your 50 th anniversary ATAGC Learning objectives:
Immune Regulation and Tolerance
Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)
Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification
Banff 1 Banff Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital Morozumi Kunio,
RENAL GRAND ROUNDS. Vitamin D- Beyond the bone. Dr Krishna Pakkivenkata. 9 th April 2010.
RENAL GRAND ROUNDS Vitamin D- Beyond the bone Dr Krishna Pakkivenkata. 9 th April 2010. Brief history Secosteroid. 1920 s-exposure to sunlight prevented rickets. 1936- structure of Vit D was discovered.
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Research article Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition Debra F. Higgins, 1 Kuniko Kimura, 2 Wanja M. Bernhardt, 3 Nikita Shrimanker, 1 Yasuhiro